clinical trial · NCT06921759
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
Eli Lilly and Company·phase3·active not recruiting·n = 206
Atopic Hand and Foot DermatitisLebrikizumabPlacebo
brief summary
The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.
started
Apr 21, 2025
primary completion
May 1, 2026
completion
Jul 1, 2026
last updated
Apr 17, 2026
official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol